Abstract. In this study we have assessed the effect of testosterone (T), dihydrotestosterone (DHT) and 5a-androstan-3a, 17b-diol (3a-diol) therapies on diabetic neuropathy. Diabetes was induced in adult male rats by the injection of streptozotocin and resulted in decreased Tand increased 3a-diol levels in plasma and in decreased levels of pregnenolone and DHT in the sciatic nerve. Moreover, a reduced expression of the enzyme converting T into DHT (i.e., the 5a-reductase) also occurs at the level of sciatic nerve, suggesting that the decrease of DHT levels could be due to an impairment of this enzyme. Chronic treatment for 1 month with DHT or 3a-diol increased tail nerve conduction velocity and partially counteracted the increase of thermal threshold induced by diabetes. Treatment with DHT increased tibial Na + ,K + -ATPase activity and the expression of myelin protein P0 in the sciatic nerve. DHT, 3a-diol and T reversed the reduction of intra-epidermal nerve fiber density induced by diabetes. These observations indicate that T metabolites can reverse behavioral, neurophysiological, morphological and biochemical alterations induced by peripheral diabetic neuropathy.
Introduction
Progressive damage of peripheral nerves represents one of the most important complications of diabetes mellitus occurring in more than 50 % of patients.
Axonal degeneration and slowing in nerve conduction velocity (NCV) reflect loss of myelinated fibers and paranodal demyelination [1, 2] . Moreover, we have recently demonstrated that the gene expression of myelin proteins, such as glycoprotein zero (P0) and peripheral myelin protein 22 (PMP22), which play a crucial role in maintaining the multilamellar structure of peripheral nerve myelin [3, 4] , is affected by diabetes [5] . Decreased Na + ,K + -ATPase activity in peripheral nerves and reduced intra-epidermal nerve fiber density associated with impaired nociceptive threshold are well described both in humans and streptozotocin (STZ)-induced neuropathy [6] [7] [8] [9] [10] [11] [12] [13] [14] . Current treatment of diabetic neuropathy relies on the control of glycemic and vascular risk factors [15] , which does not totally prevent its occurrence or progression. Recent studies showed that neuroactive steroids might provide new therapeutic options. Yorek et al. [16] observed that dehydroepiandrosterone prevents vascular and neuronal dysfunction in the sciatic nerve of STZ-treated rats. In the same model, we recently observed that progesterone (P) and its derivatives, dihydroprogesterone (DHP) and tetrahydroprogesterone (THP), reversed the impairment of NCV and thermal threshold, restored intra-epidermal nerve fiber density, improved Na + ,K + -ATPase activity, and counteracted the decrease of gene expression of myelin proteins, such as P0 and PMP22 [5] . We also observed that P administration results in a significant reduction in the number of fibers with myelin abnormalities in the sciatic nerve of STZ-treated rats [17] . Overall, the observations from experimental peripheral neuropathy models (i.e., physical trauma, aging, or genetic diseases) indicate that P and its derivatives are neuroprotective agents [18] [19] [20] [21] [22] [23] . Other neuroactive steroids exert promising neuroprotective effects. In several peripheral neuropathy models, testosterone (T) and its derivative, dihydrotestosterone (DHT), accelerate regeneration and functional recovery of nerves [24] [25] [26] [27] [28] [29] . These steroids can also exert a control on the expression of some myelin proteins. For instance, in adult male rats castration decreases the expression of P0 and PMP22 in the sciatic nerve [30, 31] . The subsequent treatment with DHT or its metabolite, 5a-androstan3a, 17b-diol (3a-diol) was able to restore the levels of P0 messenger, whereas 3a-diol induced an increase of the synthesis of PMP22 [30, 31] . A role of androgen receptor (AR) in controlling the expression of P0 was confirmed by the finding that in vivo treatment with an antagonist of this steroid receptor (i.e., flutamide) decreases the synthesis of P0 in rat sciatic nerve [31] . On this basis we hypothesized that T and its metabolites, DHT and 3a-diol, might protect peripheral nerves from degeneration induced by diabetic neuropathy. Therefore, our study was designed to assess whether plasma and sciatic nerve levels of neuroactive steroids were affected by STZ-induced neuropathy and whether in this experimental model T, DHT and 3a-diol had neuroprotective effects at neurophysiological, biochemical and neuropathological levels.
Materials and methods
Animals and treatments Animals. Two-month-old male Sprague-Dawley rats, Crl:CD BR (Charles River, Italy) were utilized. The animals were maintained in the department animal quarters with controlled temperature and humidity. The light schedule was 14 h light and 10 h dark (lights on at 06.30 h). The animals were handled following the European Union Normative (Council Directive 86/609/EEC), with the approval of our Institutional Animal Use and Care Committees. Induction of diabetes and experimental treatments. Diabetes was induced by a single intravenous injection of freshly prepared STZ (65 mg/kg; Sigma, Italy) in 0.09 M citrate buffer pH 4.8. Control animals were injected with 0.09 M citrate buffer at pH 4.8. Hyperglycemia was confirmed 48 h after STZ injection by measuring tail vein blood glucose levels using a Glucomen tester (Menarini, Italy). Only animals with mean plasma glucose levels above 300 mg/100 ml were classified as diabetic. Glycemia was also assessed before the treatment with steroids (2 months after STZ injection, see below) and tested at scheduled death, 3 months after STZ. At 2 months after the STZ injection, rats received 16 subcutaneous injections (every other day) of 1 mg T, DHT or 3a-diol (Sigma, Italy) dissolved in 200 ml sesame oil. Control rats received 200 ml vehicle (sesame oil). Rats were killed 24 h after the last treatment.
Steroids concentration in plasma and sciatic nerves Steroids in plasma and sciatic nerves were extracted according to VallØe et al. [32] with minor modification. Briefly, the internal standard deuterium-labeled 17,21,21,21-D4 pregnenolone (5 ng/ sample; D4-PREG; prepared by Dr. P. Ferraboschi, Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan, Italy) was added to the samples. The plasma sample (0.5 ml) of each animal was independently analyzed, while sciatic nerves samples from different animals were pooled to obtain a 100 mg tissue/sample. Acetic acid (1 %) in methanol was added to the samples before homogenization by sonication and loading to C18 cartridges (Discovery DSC-18, 500 mg cartridge, Supelco, Italy). The steroid fraction was eluted with methanol (5 ml) and the organic phase was reconstituted with methanol:water (1:1) before the injection in a RP-C 18 analytical column (XTerra, Waters, Ireland; 3.5 mm, 100 mm4.6 mm inner diameter). The high-performance liquid chromatograph (Surveyor LC Pump Plus, Thermo Electron Co) was coupled to an LTQ (ThermoElectron Co, USA) linear ion trap mass spectrometer (LC/MS) equipped with an atmospheric pressure chemical ionization (APCI) source operating in the positive ion mode. Each steroid was identified on the basis of the retention time and the tandem MS (MS/MS) spectrum of reference compounds. The quantitative analyses were done monitoring specific ions (selected ion chromatogram mode, SIC) in the MS/MS spectrum obtained by collision of precursor ion in MS spectrum as reported in Table 1 . Samples were quantified by means of calibration curves using a deuteriumlabeled internal standard.
Real-time PCR
Following total RNA extraction, the samples were processed for real-time PCR to assess the influence of diabetes on 5a-reductase and androgen receptor (AR) gene expression. A 1-mg aliquot of each sample was treated with DNase, to avoid DNA contamination, then reverse transcribed using a High-Capacity cDNA Archive Commercial Kit (Applera, Italy). The real-time PCR reaction was performed using the TaqMan Universal PCR Master Mix (Applera) with the specific TaqMan MGB probe purchased from Applera. Thermal cycling conditions included a pre-run of 2 min at 508C and 10 min at 958C. Cycle conditions were 40 cycles at 958C for 15 s and 608C for 1 min according to the TaqMan Universal PCR Protocol. We utilized the ABI Prism 7000 Sequence Detection System (Applera). Each sample was run in triplicate for Cell. Mol. Life Sci.
Vol. 64, 2007 Research Article the quantification of the 5a-reductase or AR gene expression as compared to the internal 18S control gene. A comparative cycle threshold (Ct) method was used to calculate the relative target gene expression. To use this method, we performed a validation experiment to demonstrate that the efficiencies of target genes amplifications and 18S rRNA were approximately equal and close to 100 %, as suggested by the manufacturer (user bulletin, No. 2; Applera). The Ct, which is the PCR cycle at which the fluorescent signal is first detectable, was then determined for all PCR reactions. For analysis, the Ct value for the internal standard (i.e., 18S RNA) was first subtracted from the Ct value for the cDNA of interest (i.e., 5a-reductase or AR). This value is denoted as the DCt. Next, the DCt value generated from control samples was subtracted from the DCt for experimental samples. This equation sets the control sample to a reference value of 0 and generates a DDCt for experimental samples. These values were averaged for each group; these mean values were used to generate the N-fold difference in RNA expression relative to the control using the equation: 2 -DDCt ; with this equation the control = 1. Although this data transformation accurately illustrates the logarithmic amplification following each PCR cycle, statistical evaluation was performed using the DDCt value. Due to the logarithmic transformation of the data, it is visually misleading to depict a standard deviation or standard error of the mean; thus real-time PCR data for 5a-reductase, do not include such error bars.
Functional analyses
Thermal nociceptive threshold. The nociceptive threshold to radiant heat was quantified using the hot plate paw withdrawal test as previously described [7] . Briefly, a 40-cm high Plexiglas cylinder was suspended over the hot plate and the temperature was maintained at 50AE0.28C. Paw withdrawal latency was defined as the time between placing the rat on the hot plate and the time of withdrawal, or licking of hindpaw, or discomfort manifested by the animal. The test was done every 2 weeks starting from the second week after STZ injection. Animals were tested twice, with a 30-min interval, in each test section. Nerve conduction velocity. At the end of the treatments antidromic tail NCV was assessed using a Myto EBNeuro electromyograph (EBNeuro, Italy) as previously described [33] . Briefly, recording ring electrodes were placed distally in the tail. The stimulating ring electrodes were placed 5 and 10 cm proximally with respect to the recording point. The latencies of the potentials recorded at the two sites after nerve stimulation was determined (peak-to-peak, stimulus duration 100 ms, filter 1 Hz-5 MHz) and NCV calculated. All the neurophysiological studies were done under standard conditions in a temperature-controlled room adjacent to the animal housing room. Skin biopsies. Peripheral nerve damage was assessed by pathological examination of the skin in the hindpaw footpad by the quantification of intra-epidermal nerve fiber density [12] . Briefly, hindpaws were collected at death. After separating the plantar glabrous skin, which included epidermis and dermis, from the underlying metatarsal bones, 3-mm round samples were taken and immediately fixed in 2 % paraformaldehyde-lysine periodate for 24 h at 48C, cryoprotected overnight, and serially cut with a cryostat to obtain 20-mm sections. Two sections from each footpad were randomly selected and immunostained with rabbit polyclonal antiprotein gene product 9.5 (PGP 9.5; Biogenesis, Poole, UK) using a free-floating protocol. Two observers blinded to the healthy or neuropathic status of rats, independently counted the total number of PGP 9.5-positive intra-epidermal nerve fibers in each section under a light microscope at high magnification, with the assistance of a microscope-mounted video camera. Individual fibers were counted as they crossed the dermal-epidermal junction, and secondary branching within the epidermis was excluded. The length of the epidermis was measured using a computerized system (Microscience Inc., Seattle, WA) and the linear density of intraepidermal nerve fibers (IENF/mm) was obtained.
Biochemical analyses Na
+ ,K + -ATPase activity. Tibial stumps were dissected out, desheathed and homogenized in chilled solution containing 0.25 M sucrose, 1.25 mM EGTA and 10 mM Tris, pH 7.5, at 1:20 (w/v) in a glass-glass Elvehjem-Potter homogenizer (DISA, Italy), and stored at -808C for ATPase determinations. Na + ,K + -ATPase activity was determined spectrophotometrically as previously described [34] . Protein content in homogenates was determined by Lowrys method [35] with bovine serum albumin as standard. cRNA probes. The specific pCR II-TOP0 (Invitrogen, Italy) plasmids contain the following inserts: 387 bp for P0, 414 bp for PMP22, and 290 bp for18 s. The cRNA antisense probes were generated by in vitro transcription of different specific pCR
II-TOP0
plasmids in presence of [ 32 P]CTP (Amersham, Italy) as the labeled nucleotide. All the cRNA probes were obtained with specific activity >10 8 cpm/mg. RNase protection assay. Total RNA from snap-frozen sciatic nerves was isolated by phenol-chloroform extraction according to the method of Chomczynski and Sacchi [36] . Samples of total RNA (10-12 mg) were utilized in the RNase protection assay, as previously described [5] . Briefly, after ethanol precipitation samples were dissolved in 20 ml hybridization solution (80 % formamide, 40 mM PIPES pH 6.4, 400 mM sodium acetate pH 6.4 and 1 mM EDTA) containing 150 000 cpm of each 32 Plabeled cRNA probe and 50 000 cpm of 32 P-labeled cRNA 18 s probe. After heating at 858C for 10 min, the probes were allowed to hybridize the endogenous RNAs at 458C overnight. Subsequently, the samples were diluted with 200 ml RNase digestion buffer (300 mM NaCl, 10 mM Tris-HCl pH 7.4, 5 mM EDTA pH 7.4) containing a 1:400 dilution of an RNase cocktail (1 mg/ml RNase A and 20 U/ml RNase T1) and incubated for 30 min at 308C. Then, 10 mg proteinase K and sodium dodecyl sulfate (10 ml of 20 % stock solution) were added to the samples and the mixture was incubated at 378C for 15 min. The samples were then extracted with phenolchloroform and precipitated with ethanol. The pellet was dried and resuspended in loading buffer (80 % formamide, 0.1 % xylene cyanol, 0.1 % bromophenol blue, 2 mM EDTA) boiled at 958C for 5 min and separated on a 5 % polyacrylamide gel, under denaturing conditions (7 M urea). The protected fragments were visualized by autoradiography and their sizes were determined using 32 P-end labeled (T4 polynucleotide kinase) MspI-digested pBR322 fragments. RNA calculation. The levels of mRNA for P0, PMP22, and 18 s rRNAwere calculated by measuring the peak densitometric area of the autoradiography analyzed with a Kodak Snap Scanner. To ensure that the autoradiographic bands were in the linear range of intensity, different exposure times were used. The mean control value within a single experiment was set to 100 and all the other values were expressed as a percentage of this. Values of controls from different experiments were all within 10 %. 
Results
As shown in Table 2 , diabetic rats had high blood glucose at the end of the experiment and, as expected, significantly less weight gain than non-diabetic control rats. Treatment with T, or its reduced derivatives, DHT and 3a-diol, did not significantly modify body weight and blood glucose levels compared to diabetic vehicle-treated rats ( Table 2) . Levels of pregnenolone (PREG), T and its metabolites, DHTand 3a-diol, present in plasma and in sciatic nerves of control and diabetic animals untreated with neuroactive steroids were assessed by LC-MS/MS. Figure 1 shows the selected ion chromatogram corresponding to each steroid analyzed. After 3 months of diabetes, PREG levels were unchanged in plasma (Fig. 2a) but were significantly decreased in sciatic nerves (Fig. 3a) . In addition, T plasma levels were significantly lowered (Fig. 2b) . A similar tendency, which however did not reach the level of significance, was also observed for the level of T measured in the sciatic nerve (Fig. 3b) . DHT levels did not change in plasma (Fig. 2c) , but a significant decrease occurred in sciatic nerves (Fig. 3c) . Furthermore, 3a-diol levels were significantly increased by diabetes in plasma (Fig. 2d ), but not in sciatic nerves (Fig. 3d) . On the basis of these observations we then evaluated whether the decrease of DHT levels in the sciatic nerve of diabetic animals might be due to an impairment of 5a-reductase (i.e., the enzyme converting T into DHT). As shown in Figure 4 , the levels of this enzyme evaluated by real-time PCR were significantly decreased in the sciatic nerve of diabetic animals untreated with neuroactive steroids. In contrast, AR levels were unmodified in sciatic nerves, i.e., data expressed as 2 -DDCt values did not show significant difference in sciatic nerve of diabetic (0.842, n=5) vs control (1.000, n=6) animals. In agreement with our previous observations, diabetes reduced tail nerve NCV by 30 % (Fig. 5 ). Chronic treatment with DHTor 3a-diol significantly improved NCV, while treatment with T was ineffective. Data in Figure 6 show that diabetes induced an increase of about 80 % in thermal threshold and that DHT and 3a-diol partially counteracted this effect, significantly decreasing the thermal latency by 38 % and 24 %, respectively. Treatment with T was ineffective. As shown in Figure 7 , diabetic rats showed a 50 % reduction in tibial Na + ,K + -ATPase activity that was partially but significantly restored by treatment with DHT (40 % increase compared to diabetic rats treated with vehicle). In diabetic rats treated with T or 3a-diol, Na + ,K + -ATPase activity showed a similar tendency without reaching a statistical significance (Fig. 7) . Skin biopsy confirmed the neuroprotective effect of T metabolites. Diabetes significantly reduced intraepidermal nerve fiber density and T, DHT and 3a-diol were able to totally restore this decrease (Fig. 8) .
In agreement with our previous observations, diabetes reduced the expression of myelin proteins, such as P0 and PMP22 (Figs 9 and 10 ). As shown in Figure 9 , treatment with DHT increased P0 mRNA levels in sciatic nerve of diabetic rat, while both T and 3a-diol were ineffective. In contrast, none of these neuroactive steroids were effective in stimulating the low PMP22 mRNA levels present in sciatic nerve of diabetic rat (Fig. 10) .
Discussion
The treatment of diabetic neuropathy represents an important challenge for biomedical research. Indeed, despite multiple attempts, no satisfactory manage- ment is yet available. We have very recently observed that STZ-induced diabetes causes P plasma levels to drop steeply in male rats and that treatment with this neuroactive steroid and its metabolites, DHP and THP, exert important protective effects on peripheral nerve damage [5] . Indeed, chronic treatment with these neuroactive steroids significantly improved NCV, thermal threshold, intra-epidermal nerve fiber density, Na + ,K + -ATPase activity, and gene expression of important peripheral myelin proteins, such as P0 and PMP22 [5] . Moreover, P administration also resulted in a significant reduction of myelin abnormalities observed in the sciatic nerve of STZ treated rats [17] . In agreement with observations showing dysfunction in reproductive axis associated with diabetes [37] [38] [39] [40] [41] [42] [43] [44] [45] , we here demonstrate that T plasma levels are also significantly decreased in STZ-treated rats. Moreover, our data indicate that diabetes causes alterations in the levels of steroids in sciatic nerves that do not completely reflect the changes observed in plasma. Indeed, the decrease in T levels observed in the plasma of diabetic rats was not detected in the sciatic nerves. In addition, diabetes significantly decreases PREG and DHT levels in sciatic nerves but does not affect the levels of these steroids in plasma. Conversely, the levels of 3a-diol were significantly increased in the plasma of diabetic rats, while they remained unchanged in the sciatic nerves. These findings suggest that diabetes differentially alters steroid synthesis in endocrine glands and in sciatic nerves. Formation of PREG and other steroids in sciatic nerve is not surprising. It has been clearly established that Schwann cells express molecules able to participate in the transport of cholesterol to the inner mitochondrial membrane where cytochrome P450scc (i.e., the enzyme forming PREG) is located [46] . Indeed, the expression of the peripheral benzodiazepine receptor (PBR, now re-named translocator protein-18kDa [47] ), of its endogenous ligand octadecaneuropeptide [48] [49] [50] , and of the steroidogenic acute regulatory (StAR) protein has been demonstrated [51] . Altered levels of neuroactive steroids in peripheral nerves have been also reported in other experimental models. For instance, the expression of PBR is increased in Schwann cells after nerve lesion, and returns to normal levels when regeneration is completed [49] . This induction has been interpreted as an endogenous neuroprotective response to the damage. The changes are in keeping with the evidence that P biosynthesis is up-regulated in the spinal cord of rats Cell. Mol. Life Sci.
Vol. 64, 2007 Research Article 1163 with STZ-induced diabetes [52] . Furthermore, it has been observed that neurosteroidogenesis is altered in an animal model of neuropathic pain. Indeed, sciatic nerve ligature increased the expression of cytochrome P450-scc in spinal and supra-spinal networks and raised the concentrations of PREG and THP in the spinal cord [53] . In the context of diabetes, this finding could be very interesting because neuropathic pain is an important component of diabetic neuropathy. The decrease of DHT in the sciatic nerves of diabetic rats reported here does not seem to be the consequence of the reduced levels of the general precursor PREG, since the levels of T, the direct precursor of DHT, were not significantly affected by diabetes. Consequently, the decreased levels of DHT probably reflect an impairment of the enzyme devoted to its production (i.e. , the enzyme 5a-reductase that converts T into DHT). In agreement with this hypothesis, we have observed that the mRNA levels of 5a-reductase are significantly decreased in the sciatic nerve after 3 months of diabetes. On the other hand, the decrease of DHT in diabetic sciatic nerve could be also due to an increase of DHT metabolism. Indeed, it has been demonstrated that DHT may be further converted into 3a-diol, by the action of the enzyme 3a-hydroxysteroid dehydrogenase (3a-HSD), as well as in androstanedione, by the action of the enzyme Figure 6 . DHT and 3a-diol significantly improve the impaired sensitivity in diabetic rats. The heat sensitivity threshold is expressed as withdrawal latency in seconds and was evaluated at the beginning (a) and end of treatment (b) in control (C) and in diabetic rats treated with vehicle only (V), or with T, DHT, or 3a-diol. Data are mean AE SEM (number of rats in each group in parentheses). ANOVA followed by Tukey-Kramer post-test; ** p<0.01 vs control; *** p<0.001 vs control; # p<0.05 vs diabetic injected with vehicle; ### p<0.001 vs diabetic injected with vehicle. 17b-hydroxysteroid dehydrogenase. These metabolic pathways have been extensively described in peripheral tissues [54] , but scarce observations are available for peripheral nerves. We previously demonstrated that in vitro rat sciatic nerve actively converts T into DHT and subsequently into 3a-diol [55] . In agreement with this previous observation, here we detected 3a-diol levels in sciatic nerve. However, the levels of this metabolite were not affected by diabetes, suggesting that a modification in the conversion of DHT into 3a-diol is not contributing to the decreased DHT levels in the sciatic nerve of diabetic rats. However, an effect of diabetes on the conversion of DHT into androstanedione cannot be excluded. Based on the finding reported here that both steroid plasma and tissue levels are affected by diabetes, and that P and its derivatives can reverse peripheral nerve degeneration [5] , we investigated if T and its derivatives, DHT and 3a-diol, have similar effect in STZinduced neuropathy. We found that DHT and 3a-diol exert a neuroprotective effect at biochemical, neuropathological and neurophysiological level. In particular, DHT was able to reverse the alterations induced by diabetes on NCV, thermal threshold, intra-epidermal nerve fiber density, Na + ,K + -ATPase activity and expression of myelin protein P0. This latter effect is in agreement with what we previously observed in nondiabetic animals [30, 31] . The neuroprotective activity of DHT could be mediated by the interaction with AR. DHT has a much higher affinity for AR than T [56] , and, as demonstrated here by real-time PCR, the expression of this steroid receptor is not modified in the sciatic nerve of diabetic male rat. Treatment with T significantly restored intra-epidermal nerve fiber density, although for the other parameters considered here only a tendency to restoration was observed, which, however, did not reach a statistical significance. This partial neuroprotective effect of T compared with its derivatives might be explained by the reduced expression of 5a-reductase in the sciatic nerve of diabetic rats. Indeed, very low levels of DHT could be locally formed in diabetic male rats treated with T. Our findings indicate that the metabolite of DHT, 3a-diol, is also effective in counteracting the effects of diabetes on NCV, thermal threshold and intra-epidermal nerve fiber density. Although 3a-diol is unable to directly bind AR [56] , it can be back-converted to DHT and consequently exert its effects through activation of AR. This can occur since the conversion of DHT into 3a-diol by the enzyme 3a-hydroxysteroid dehydrogenase is a reversible process [57] . On the other hand, 3a-diol may potentially interact with the estrogen receptor b (ERb), another classical steroid receptor. Observations obtained by Pak et al. [58] indicate that 3a-diol is able to mediate the transcription preferentially through a splice variant of ERb (i.e., ERb 2), which has been identified in several rat tissues, including the brain [59] . In addition, recent data suggest that some of the effects of 3a-diol to enhance learning could be mediated through ERb localized in the hippocampus [60] . Although ERb has not been directly assessed in the sciatic nerves of adult animals, its expression is very low in Schwann cells cultured from sciatic nerves of neonatal rats [61] . However, the expression of ERb is increased in motor neurons of the spinal cord after sciatic nerve injury [62] , and may therefore be involved in the mechanisms of nerve regeneration. Another possible pathway mediating the effect of 3a-diol could be the interaction with GABA-A receptor [63, 64] , which is present both in sciatic nerve and in Schwann cells [65] . Diabetes seems to affect the ability of neuroactive steroids to interact with this receptor, at least in Schwann cells. For instance, at variance to that observed in non-diabetic animals [30, 31] , as demonstrated here, 3a-diol was ineffective in stimulating the expression of P0 and PMP22 in diabetic animals. This is in agreement with our previous observations for another neuroactive steroid, THP. Indeed, THP, which is well know as a potent ligand of GABA-A receptor [66] , is able to increase the expression of P0 and PMP22 [65] in non-diabetic animals, but was ineffective in diabetic animals [5] . In conclusion, our findings indicate that DHT and 3a-diol exert neuroprotective actions against the pathological changes induced by experimental diabetes in peripheral nerves. These findings suggest that T metabolites may represent a promising therapeutic strategy for the treatment of diabetic neuropathy. 
